Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

CONCLUSION: DRd is associated with a significantly lower risk of disease progression or death compared to VRd as 1L treatment for TIE NDMM patients.PMID:37838502 | DOI:10.1016/j.clml.2023.09.003

Source: Clinical Lymphoma and Myeloma - October 14, 2023 Category: Cancer & Oncology Authors: Lucio Navarro Gordan Carlyn Rose Tan Robert Vescio Jing Christine Ye Carolina Schinke Rohan Medhekar Alex Z Fu Marie-H élène Lafeuille Philippe Thompson-Leduc Vipin Khare John Reitan Gary Milkovich Shuchita Kaila Faith Davies Saad Z Usmani Source Type: research